Fig. 2: Consort diagram for 1138 non-T acute lymphoblastic leukemia (non-T ALL) patients treated in the Japan Association of Childhood Leukemia Study Group (JACLS) ALL-02 study. | Blood Cancer Journal

Fig. 2: Consort diagram for 1138 non-T acute lymphoblastic leukemia (non-T ALL) patients treated in the Japan Association of Childhood Leukemia Study Group (JACLS) ALL-02 study.

From: Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02

Fig. 2: Consort diagram for 1138 non-T acute lymphoblastic leukemia (non-T ALL) patients treated in the Japan Association of Childhood Leukemia Study Group (JACLS) ALL-02 study.

Non-T ALL patients (n = 1138) were stratified into standard risk (SR), high risk (HR), and extremely HR (ER) groups, based on age, initial white blood cell count, and initial response to prednisolone. Then, patients were re-stratified into SR, HR, ER, and failure (F) groups based on Day 15 and Day 33 bone marrow status.

Back to article page